Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP1138 | DOI: 10.1530/endoabs.81.EP1138

1University of Pisa, Department of Clinical and Experimental Medicine, Italy; 2University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Area, Italy; 3Azienda Ospedaliero-Universitaria Pisana, Department of Emergency Medicine, Italy; 4University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Italy


Autoimmune thyroid diseases (AITD) are organ specific autoimmune disorders with a T-cell-mediated immune attack directed against the thyroid. Hashimoto’s thyroiditis and Graves’ disease are the two principal AITD clinical presentations, which are characterized by hypothyroidism and thyrotoxicosis, respectively. We review the available data in literature about personalized medicine in patients with autoimmune thyroiditis (AT) and hypothyroidism. The synthetic Levothyroxine (L-T4) (1.5-1.7 μg/kg) is the daily treatment for these patients. L-T4 is available in different formulations, including tablet, liquid solution, or soft gel capsule. The tablets are the most prescribed, while the liquid, or the soft gel capsules formulations, are generally administered in hypothyroid patients who have issues of malabsorption, or who are in treatment with drugs interfering with L-T4 absorption. Furthermore, the administration of myoinositol and seleno-methionine in patients with subclinical hypothyroidism and AT showed promising effect; with a significant decline in TSH and antithyroid autoantibodies levels. Actually, myoinositol, which is the precursor of phosphoinositides and takes part into various cellular processes, has also a key role in thyroid autoimmunity and function. Moreover, thyroidectomy can be suggested in patients with AT, owing to a variety of reasons such as: important signs or symptoms of local compression; the presence of thyroid nodules with “suspicious” features; cosmetic reasons for a goiter. Recently, a randomized trial suggested that total thyroidectomy, but not medical therapy, can ameliorate fatigue and quality of life in these patients. Further researches involving larger population will help in the evaluation of the effect of these novel treatments on the quality of life in these patients.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.